Rigel Pharmaceuticals, Inc.

This biotechnology company develops and provides new therapies for patients with blood disorders and cancer, focusing on products that target critical disease mechanisms. Its first FDA-approved product is TAVALISSE® (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor. TAVALISSE is approved for adult patients with chronic immune thrombocytopenia (ITP) who have not responded sufficiently to previous treatments. It is also available in Europe and the United Kingdom as TAVLESSE, and in Japan, the Republic of Korea, Canada, and Israel as TAVALISSE for chronic ITP in adults. The company's second FDA-approved product is REZLIDHIA® (olutasidenib), indicated for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test. The company in-licensed REZLIDHIA from Forma Therapeutics, Inc., now Novo Nordisk, in July 2022, securing exclusive worldwide rights for its development, manufacturing, and commercialization. GAVRETO® (pralsetinib) is the company's third FDA-approved product, commercialized starting June 2024. GAVRETO is a once-daily, small molecule, oral kinase inhibitor targeting wild-type rearranged during transfection (RET) and oncogenic RET fusions. It is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory. The company acquired the US rights for GAVRETO from Blueprint Medicines Corporation, now a Sanofi SA company, in February 2024.